(Albany, US) DelveInsight has launched a new report on Complement 3 Glomerulopathy Market
DelveInsight’s “Complement 3 Glomerulopathy (C3G) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Complement 3 Glomerulopathy (C3G) , historical and forecasted epidemiology as well as the Complement 3 Glomerulopathy (C3G) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Complement 3 Glomerulopathy (C3G) market report provides current treatment practices, emerging drugs, Complement 3 Glomerulopathy (C3G) market share of the individual therapies, current and forecasted Complement 3 Glomerulopathy (C3G) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Complement 3 Glomerulopathy (C3G) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market
The term Complement 3 glomerulopathy (C3G) was adopted by expert consensus in 2013 to define a group of rare kidneys diseases driven by dysregulation of the complement cascade. It is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The term C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when observed under a microscope. People with DDD generally present at a younger age (childhood or adolescence) compared to people with C3GN (adulthood). In DDD, C3 deposits are bunched up in one area of the glomeruli and appear thick while in case of C3GN, C3 deposits are more spread out and less thick. Progression to end-stage renal disease (ESRD) has been found in 40% of C3G patients, with no detectable difference between those with C3GN versus DDD.
Request for free sample page:- https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Complement 3 Glomerulopathy Treatment
Optimal treatment for C3G has not been established yet since no treatment has proven effective and beneficial for C3G. Recommendations have only been deducted from case series and observational studies and are mostly based on expert opinion. As a consequence, its treatment has not been standardized and is concentrated in centres of expertise. All patients diagnosed with C3G should be treated with renoprotective measures, including lifestyle advice, an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker to control hypertension and proteinuria, and lipid-lowering treatment. Such medication alone has not been shown to protect against progression to end-stage renal disease but may improve the protective effect of immunosuppressive medication.
Complement 3 Glomerulopathy Market
Since there are no approved therapies for C3G, the market is mainly dominated by the use of off-label prescription drugs. Treatments for C3G include Immunosuppressant, Steroids, Renin–angiotensin–aldosterone system Inhibitors (RAAS), and other Supportive therapies (also including Antibody regimens: Eculizumab and Rituximab). The current emerging market of C3G possesses an intermediate pipeline. Expected Launch of potential therapies, Danicopan (Alexion Pharmaceuticals), Narsoplimab (Omeros Corporation), Pegcetacoplan (Apellis Pharmaceuticals), ChemoCentryx (Avacopan; Phase II), and LNP023 (Novartis Pharmaceuticals) during the forecast period of 2020-2030, may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of C3G. In addition, there are few early stage key players, namely, Amyndas Pharmaceuticals (AMY-101; Phase I) and Visterra Inc.(Preclinical Stage) that are investigating their drug candidates for the treatment of patients with C3G as well. Since there are no approved therapies for C3G, the market is mainly dominated by the use of off-label prescription drugs. Treatments for C3G include Immunosuppressant, Steroids, Renin–angiotensin–aldosterone system Inhibitors (RAAS), and other Supportive therapies (also including Antibody regimens: Eculizumab and Rituximab). The current emerging market of C3G possesses an intermediate pipeline. Expected Launch of potential therapies, Danicopan (Alexion Pharmaceuticals), Narsoplimab (Omeros Corporation), Pegcetacoplan (Apellis Pharmaceuticals), ChemoCentryx (Avacopan; Phase II), and LNP023 (Novartis Pharmaceuticals) during the forecast period of 2020-2030, may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of C3G. In addition, there are few early stage key players, namely, Amyndas Pharmaceuticals (AMY-101; Phase I) and Visterra Inc.(Preclinical Stage) that are investigating their drug candidates for the treatment of patients with C3G as well.
Complement 3 Glomerulopathy Report Scope
Download free sample page: – https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market
Table of content
1. Key Insights
2. Executive Summary of Complement 3 Glomerulopathy (C3G)
3. Competitive Intelligence Analysis for Complement 3 Glomerulopathy (C3G)
4. Complement 3 Glomerulopathy (C3G) : Market Overview at a Glance
5. Complement 3 Glomerulopathy (C3G) : Disease Background and Overview
6. Patient Journey
7. Complement 3 Glomerulopathy (C3G) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Complement 3 Glomerulopathy (C3G) Treatment
11. Marketed Products
12. Emerging Therapies
13. Complement 3 Glomerulopathy (C3G) : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Complement 3 Glomerulopathy (C3G)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/